When will the patents on BENZYL BENZOATE expire, and when will BENZYL BENZOATE go generic?

Sponsor	Phase
College of Physicians and Surgeons Pakistan	EARLY_PHASE1
University of Aleppo	PHASE3
Tishreen University Hospital	PHASE3

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Lannett	BENZYL BENZOATE	benzyl benzoate	EMULSION;TOPICAL	084535-001	Approved Prior to Jan 1, 1982		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: August 8, 2026

Benzyl benzoate is a mature, low-cost pharmaceutical and industrial chemical with limited standalone financial transparency. Its pharmaceutical demand is concentrated in topical scabies and lice treatments, while a larger share of global volume likely comes from fragrance, flavor, solvent, and veterinary applications. The product has no meaningful core-patent barrier, no biosimilar pathway, and limited U.S. branded-market protection. Financial performance therefore depends on manufacturing cost, regulatory registrations, institutional procurement, regional disease burden, and supply reliability rather than exclusivity.

What is benzyl benzoate used for in the pharmaceutical market?

Benzyl benzoate is an ester of benzyl alcohol and benzoic acid, identified by CAS Registry Number 120-51-4. Pharmaceutical uses include topical treatment for scabies and, in some markets, pediculosis. It is generally supplied as a lotion, emulsion, cream, or diluted topical preparation, commonly at concentrations between 10% and 25% depending on age group, jurisdiction, and product labeling.

The product is also used as:

A veterinary ectoparasiticide.
A fragrance fixative.
A solvent for musk and other fragrance ingredients.
A component in some cosmetic and personal-care products.
An excipient or processing ingredient in selected formulations.

The pharmaceutical market is therefore only one part of the benzyl benzoate value chain. Industrial and personal-care demand can influence active pharmaceutical ingredient, or API, supply and pricing.

Which diseases drive benzyl benzoate demand?

Scabies is the principal human-health demand driver. The World Health Organization identifies benzyl benzoate as one topical treatment option for scabies, although treatment choice varies by country, age group, pregnancy status, resistance patterns, and procurement policy.[1]

Benzyl benzoate is usually positioned against:

Permethrin 5% cream.
Ivermectin tablets.
Sulfur ointment.
Crotamiton.
Lindane, where still permitted.
Malathion and pyrethroid products for lice.

Permethrin is generally the stronger first-line competitor in many high-income markets because of established labeling, physician familiarity, and broad availability. Benzyl benzoate remains relevant where low acquisition cost, local manufacturing, or public-health procurement outweighs convenience and tolerability.

How large is the benzyl benzoate pharmaceutical market?

No audited global revenue series isolates pharmaceutical benzyl benzoate sales. Public-company filings generally aggregate the product into broader generic, dermatology, consumer-health, chemical, or contract-manufacturing revenue categories. Commercial market reports often combine pharmaceutical, cosmetic, fragrance, and industrial uses, producing figures that are not directly comparable.

The market can be characterized as fragmented and low value per treatment unit:

Market characteristic	Assessment
Product maturity	Very mature
Core pharmaceutical IP	Effectively expired
U.S. branded concentration	Low
Generic competition	High
Average unit value	Low relative to modern dermatology drugs
Primary dosage form	Topical lotion, emulsion, or cream
Main demand variable	Scabies prevalence and procurement volume
Major commercial risk	Price competition and supply interruptions
Revenue visibility	Poor at individual-product level
Growth profile	Low to moderate, with episodic regional surges

The absence of standalone revenue disclosure limits the usefulness of top-down market estimates. For investment analysis, benzyl benzoate should be treated as a product-family or portfolio contributor rather than as a separately valued pharmaceutical franchise.

What is the financial trajectory for benzyl benzoate?

The financial trajectory is structurally mature rather than innovation-led. Revenue growth is more likely to come from volume, geographic expansion, new registrations, and supply contracts than from price increases.

Historical trajectory

Benzyl benzoate entered commercial use decades ago. Its low synthesis complexity and broad industrial availability have prevented the development of a durable branded premium. The pharmaceutical product has moved through the standard generic lifecycle:

Initial therapeutic adoption.
Broad generic and compounded availability.
Price compression.
Continued use in lower-cost and public-health settings.
Demand stabilization with periodic outbreak-related increases.

There is no comparable late-stage patent cliff because the core compound and conventional topical uses are old. The commercial decline of any individual branded product does not eliminate demand for the molecule itself.

Near-term trajectory

Near-term pharmaceutical revenue is likely to remain stable to modestly growing in markets with:

Persistent scabies transmission.
Public-health or humanitarian treatment programs.
Limited access to permethrin or ivermectin.
Local generic manufacturing.
Veterinary parasiticide demand.
Growing pharmaceutical and personal-care production.

The principal constraint is substitution. Permethrin and oral ivermectin can displace benzyl benzoate where treatment adherence, dosing convenience, or guideline preference favors those alternatives.

Margin trajectory

Margins are likely to remain under pressure because:

The API is chemically simple.
Multiple regional manufacturers can supply it.
Topical products are comparatively easy to formulate.
Switching costs for buyers are low.
Public tenders often award contracts primarily on price and compliance.
Retail products compete with compounded and imported alternatives.

Manufacturers can improve margin through controlled-release emulsions, lower-irritancy vehicles, pediatric formulations, combination products, and reliable regulatory documentation. These opportunities are incremental and generally do not create durable pricing power unless supported by registered formulation claims or a differentiated delivery system.

What patents protect benzyl benzoate products?

No meaningful unexpired patent estate protects benzyl benzoate as a compound. The molecule is a long-established chemical entity, and conventional scabies and lice uses are not expected to carry commercially relevant core-patent protection.

The relevant IP analysis is therefore formulation-specific:

IP category	Commercial relevance
Compound patent	None expected to remain active
Conventional topical-use patent	Generally expired or unavailable
Novel emulsion or cream	Possible, but narrow
Combination treatment	Possible, depending on claims
Manufacturing process	Possible, but usually design-around risk is high
Packaging or applicator	Possible, with limited exclusionary value
Trademark	May support brand recognition but not molecule exclusivity
Trade secret	May protect process know-how without blocking competitors

What formulations are protected by benzyl benzoate patents?

A company could seek patents on a specific formulation containing benzyl benzoate, such as:

A low-irritancy emulsion.
A pediatric formulation.
A controlled-release topical system.
A combination with another scabicide.
A formulation improving skin penetration or wash-off performance.
A preservative system that extends shelf life.
A metered-dose or unit-dose delivery device.

Such patents would protect the claimed formulation or method, not benzyl benzoate generally. Their strength would depend on claim breadth, clinical differentiation, enablement, prior art, and whether competing products can be reformulated without infringement.

What is the FDA regulatory and Orange Book status of benzyl benzoate?

Benzyl benzoate has limited U.S. regulatory exclusivity. The FDA Orange Book is designed to identify approved drug products, therapeutic equivalence evaluations, patent listings, and exclusivity information. It does not provide a meaningful patent or exclusivity platform for conventional benzyl benzoate topical products.[2]

U.S. products may appear through different regulatory and commercial channels, including:

Prescription topical products.
Compounded preparations.
Imported products.
Nonprescription or enforcement-policy-dependent products.
Veterinary products regulated under separate frameworks.
Cosmetic or industrial products not marketed for drug claims.

The presence of a benzyl benzoate listing in a commercial drug database does not establish FDA approval. Product status must be assessed by the specific manufacturer, label, National Drug Code, application number, and approved indication.

Does benzyl benzoate have FDA exclusivity?

No commercially significant period of new chemical entity exclusivity is associated with benzyl benzoate. A new formulation or combination could theoretically receive limited regulatory exclusivity if it met applicable requirements, but the old molecule itself does not generate new chemical entity protection.

When does benzyl benzoate lose exclusivity?

Benzyl benzoate has already lost practical molecular exclusivity. There is no central future loss-of-exclusivity date comparable to a patented specialty drug.

The relevant dates are product-specific:

Patent expiration for any later formulation patent.
Expiration of a manufacturer’s regulatory exclusivity, if applicable.
Loss of a national marketing authorization.
Termination of a tender or supply contract.
Withdrawal of a branded product.
Expiration of a trademark or registration.

A generic launch does not require a Paragraph IV strategy when no relevant listed patent blocks approval. A company could still file a patent certification or challenge if a particular approved reference product had listed patents, but this is not the expected market structure for conventional benzyl benzoate.

Which companies compete in the benzyl benzoate market?

Competition is fragmented across API producers, generic pharmaceutical companies, compounding pharmacies, contract manufacturers, veterinary suppliers, and chemical distributors. The identity of the leading supplier varies by country and by product category.

The competitive landscape generally includes:

Indian and Chinese API manufacturers.
Regional generic-drug manufacturers.
European and Latin American topical-product companies.
Contract development and manufacturing organizations.
Veterinary pharmaceutical companies.
Fragrance and specialty-chemical producers.

Large multinational pharmaceutical companies are not expected to derive material reported revenue from benzyl benzoate alone. The product is more commercially relevant to companies with portfolios in dermatology, anti-infectives, neglected tropical diseases, veterinary parasiticides, or low-cost essential medicines.

How does benzyl benzoate compare with permethrin and ivermectin?

Factor	Benzyl benzoate	Permethrin	Ivermectin
Primary delivery	Topical	Topical	Oral and topical
Patent position	Mature, no core exclusivity	Mature, mostly generic	Mature, mostly generic
Treatment convenience	Lower	Moderate	Higher for selected patients
Irritation risk	Can be significant	Generally better tolerated	Systemic exposure
Public-health use	Established in lower-cost settings	Broadly established	Increasingly important
Manufacturing complexity	Low	Low to moderate	Higher than benzyl benzoate
Price competition	Very high	High	Variable
Main commercial advantage	Low cost and availability	Familiarity and tolerability	Convenience and mass-treatment suitability

Benzyl benzoate can retain share where cost is decisive. It is weaker where patient adherence, pediatric tolerability, or physician preference dominates.

What generic entry risks exist for benzyl benzoate?

Generic entry risk is already embedded in the market. The principal risk is not a future wave of entrants but ongoing substitution among existing suppliers.

Key risks include:

API price undercutting.
Regulatory noncompliance by low-cost suppliers.
Product recalls caused by contamination or stability failures.
Inconsistent concentration or emulsion quality.
Retail substitution by permethrin.
Public procurement switching to ivermectin.
Limited physician prescribing in high-income countries.
Consumer reluctance caused by odor, irritation, or multiple-application requirements.

A manufacturer with a registered, stable, well-tolerated formulation can defend share through quality and supply reliability, but these advantages usually support contract retention rather than high margins.

What manufacturing and IP barriers affect benzyl benzoate?

Manufacturing barriers are modest at the chemical level. Production generally relies on esterification of benzyl alcohol and benzoic acid, followed by purification and quality control. Commercial barriers arise from compliance rather than synthesis.

Relevant requirements include:

API identity and purity testing.
Residual-solvent control.
Impurity profiling.
Stability data.
Microbiological control for topical products.
Good Manufacturing Practice compliance.
Validated fill-finish and packaging operations.
Regional registration and pharmacopoeial conformity.

The main IP barrier is formulation-specific. A manufacturer may avoid a patent on a branded emulsion by changing excipients, concentration, delivery device, or manufacturing sequence. Process patents are generally vulnerable to design-around strategies unless they cover a genuinely efficient or technically distinctive process.

What patent litigation and licensing activity affect benzyl benzoate?

Benzyl benzoate has no known litigation profile comparable to patented oncology, immunology, or cardiovascular drugs. Paragraph IV litigation is not a central market feature. Licensing activity is more likely to involve:

Regional distribution.
Contract manufacturing.
API supply.
Veterinary product registrations.
Public-health procurement.
Rights to a particular topical formulation or combination.

Licensing economics are therefore modest. A deal would likely be based on territory, volume, registration status, and manufacturing capacity rather than a royalty-bearing molecular patent.

What is the geographic outlook for benzyl benzoate?

Demand is geographically uneven.

North America and Western Europe

Markets are relatively mature and competitive. Permethrin, ivermectin, and alternative topical products constrain benzyl benzoate growth. Commercial opportunity is concentrated in niche dermatology, compounding, imported products, and veterinary applications.

Latin America

Benzyl benzoate has stronger historical recognition and may retain use in topical antiparasitic products. Pricing and regulatory registration are important competitive variables.

Asia-Pacific

The region combines high manufacturing capacity with substantial dermatology, generic, veterinary, and industrial demand. India and China are important supply bases, while local scabies prevalence supports regional pharmaceutical consumption.

Africa and humanitarian markets

The greatest volume opportunity may arise from scabies-control programs, institutional procurement, and donor-supported treatment campaigns. However, these markets are price sensitive and may be affected by supply tenders, donor priorities, and availability of permethrin or ivermectin.

What is the investment outlook for benzyl benzoate?

Benzyl benzoate is a defensive, volume-driven product rather than a high-growth pharmaceutical asset. Its investment value is strongest when embedded in a broader platform with:

Low-cost API production.
Dermatology or anti-infective distribution.
Government and institutional contracts.
Veterinary exposure.
Multi-country registrations.
Reliable topical manufacturing.
Access to fragrance and specialty-chemical demand.

The product is a weak standalone investment thesis because revenue is difficult to isolate, pricing power is limited, and no major patent catalyst is visible. The most credible upside comes from operational scale, recurring tenders, geographic expansion, and differentiated formulations.

Key Takeaways

Benzyl benzoate is a mature, low-cost scabicide and industrial chemical.
Pharmaceutical demand is concentrated in topical scabies and lice treatment, with additional veterinary use.
No meaningful core patent or regulatory exclusivity protects the molecule.
The FDA Orange Book does not provide a significant patent-based barrier for conventional benzyl benzoate products.
Paragraph IV litigation and biosimilar risk are not material market factors.
Revenue is fragmented and generally not disclosed separately by public companies.
Permethrin and ivermectin are the principal therapeutic competitors.
Financial performance depends on volume, tenders, manufacturing efficiency, and registration coverage.
Formulation patents may create narrow protection but are unlikely to establish molecule-level exclusivity.
The strongest commercial opportunities are in low-cost generics, public-health procurement, veterinary products, and integrated chemical-pharmaceutical manufacturing.

FAQs

Is benzyl benzoate still commercially relevant?

Yes. It remains relevant as a low-cost topical scabicide, veterinary antiparasitic, fragrance ingredient, and specialty chemical, although its pharmaceutical role is smaller than that of permethrin and ivermectin in many markets.

Is benzyl benzoate an essential medicine?

Its status varies by national formulary. It is recognized in international scabies-treatment guidance, but national essential-medicine listings and procurement policies differ.[1]

Can a company patent a new benzyl benzoate cream?

Yes. A novel cream, emulsion, delivery system, combination, or manufacturing process may be patentable if it meets novelty, inventive-step, and other applicable legal requirements. The patent would cover the claimed innovation rather than the old active ingredient.

Is benzyl benzoate safer than permethrin?

Safety depends on concentration, formulation, age, skin condition, exposure, and treatment adherence. Benzyl benzoate can cause skin irritation, while permethrin is often preferred for tolerability. Product-specific labeling and local clinical guidance control use.

Does benzyl benzoate have biosimilar competition?

No. Biosimilars apply to biologic medicines. Benzyl benzoate is a small-molecule chemical and competes through generic, branded-generic, compounded, and formulation-based channels.

References

World Health Organization. (2023). Scabies. https://www.who.int/news-room/fact-sheets/detail/scabies
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
U.S. National Library of Medicine. (2024). Benzyl benzoate: Drug information and labeling resources. DailyMed. https://dailymed.nlm.nih.gov/
U.S. National Library of Medicine. (2024). Benzyl benzoate. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/Benzyl-benzoate
Centers for Disease Control and Prevention. (2024). Parasites: Scabies. https://www.cdc.gov/scabies/

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	118
Clinical Trials:	6
Patent Applications:	2,357
DailyMed Link:	BENZYL BENZOATE at DailyMed

AI Deep Research

Questions you can ask:

Summary for BENZYL BENZOATE

Recent Clinical Trials for BENZYL BENZOATE

Anatomical Therapeutic Chemical (ATC) Classes for BENZYL BENZOATE